A committee of experts voted on a preference for the Moderna or Pfizer immunizations, citing the risk of blood clots linked to Johnson & Johnson’s product.
Tag: Advisory Committee on Immunization Practices
C.D.C. Panel Endorses Third Vaccine Shot for Immunocompromised
The added dose will bolster protection for people who have weakened immune systems because of cancer treatments, transplant surgery and other medical interventions.
Heart Problems After Vaccination Are Very Rare, Federal Researchers Say
More than 1,200 cases have been reported, mostly mild and more often in young men and boys. The benefits of vaccination still far outweigh the risks, experts said.
C.D.C. Advisers Endorse Pfizer Vaccine for Children Ages 12 to 15
Immunizations will quickly begin nationwide, officials predicted.
J.&.J. Vaccine Will Be Available Again Soon
U.S. experts weigh the risks for younger women and cases of a rare blood-clotting disorder, and lift the pause in giving the one-shot vaccine.
C.D.C. Panel to Meet Next Friday on J.&J. Vaccine Pause
The advisory panel will discuss safety data related to a small number of blood-clotting cases in Johnson & Johnson vaccine recipients. It is unclear whether the vaccine was responsible for the clots.
A panel of independent experts to the C.D.C. says it needs more time to assess data and risks during the Johnson & Johnson vaccine pause.
The emergency meeting on Wednesday came after federal health authorities said they were studying rare blood clots in a small number of vaccine recipients and injections of the vaccine were halted across the country.
Expert Panel to C.D.C. to Vote on Johnson & Johnson Vaccine Pause
The emergency meeting comes after federal health authorities said they were studying rare blood clots in six vaccine recipients and injections of the vaccine were halted across the country.
C.D.C. Panel Affirms Johnson & Johnson Vaccine, as Expected
The committee’s approval echoed the Food and Drug Administration’s decision on Saturday to authorize the vaccine for emergency use.